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Abstract
Estrogens are pleiotropic steroid hormones with pro- and anti-inflammatory effects that influence
autoimmune disease and pregnancy. Both autoimmunity and pregnancy are similar to cancer with regard
to the immune system. In established tumors, as is the case in autoimmune disease and pregnancy, the
host is exposed to self or allogeneic antigens, which are capable of eliciting immune responses. However,
for pregnancies to remain viable, autoimmune disease patients survive, and tumors to persist, the
immune system must be at least partially tolerized to these challenges. Therefore, I hypothesize that, just
as they appear to influence pregnancy and autoimmunity, estrogens’ ability to mediate inflammation and
the resulting immune response is a crucial factor in tumor progression. Clinically, antiestrogens are
effective adjuvant therapy in estrogen-dependent, receptor (ER) positive breast cancer; however, little is
known about their potential role in cancers that are not thought to be estrogen-dependent, such as
ovarian cancer. Outside of its direct proliferative effect in ER+ breast tumors, little is known about the
effect of estrogen signaling on the tumor microenvironment, despite normal cell ER positivity in a variety
of tumors. Using immunocompetent mouse models, we demonstrate that systemic estrogen levels have
an important effect on antitumor immunity. Independent of neoplastic cell signaling, estrogens promote
tumor progression by directly and indirectly suppressing antitumor T cell responses. Estrogen-driven
decreases in antitumor T cell effector activity correspond with a large, cell-intrinsic increase in monocytic
and granulocytic myeloid-derived suppressor cells (MDSCs). We show that estrogen signaling increases
responsiveness to tumor-initiated inflammatory signals to augment STAT3 activation during myeloid cell
differentiation. Estrogen increases the expression of activating kinases, such as Jak2, in bone marrow
progenitor cells thus priming the host to respond to tumor-driven IL-6 by producing more MDSCs. Without
estrogen signaling, MDSC differentiation and suppressive activity is greatly diminished. Therefore,
estrogens are able to play an important role in potentiating a suppressive ovarian tumor
microenvironment. This work suggests that antiestrogens have clinical potential in a wide variety of
tumors, especially in combination with immunotherapies or chemotherapies targeting pathways critical
for MDSC differentiation.
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ABSTRACT

ESTROGENS IMPAIR ANTITUMOR IMMUNITY BY PROMOTING THE
ACCUMULATION OF MYELOID-DERIVED SUPPRESSOR CELLS
Nikolaos Svoronos
José R. Conejo-Garcia, MD, PhD

Estrogens are pleiotropic steroid hormones with pro- and anti-inflammatory effects that
influence autoimmune disease and pregnancy. Both autoimmunity and pregnancy are
similar to cancer with regard to the immune system. In established tumors, as is the case
in autoimmune disease and pregnancy, the host is exposed to self or allogeneic antigens,
which are capable of eliciting immune responses. However, for pregnancies to remain
viable, autoimmune disease patients survive, and tumors to persist, the immune system
must be at least partially tolerized to these challenges. Therefore, I hypothesize that, just
as they appear to influence pregnancy and autoimmunity, estrogens’ ability to mediate
inflammation and the resulting immune response is a crucial factor in tumor progression.
Clinically, antiestrogens are effective adjuvant therapy in estrogen-dependent, receptor
(ER) positive breast cancer; however, little is known about their potential role in cancers
that are not thought to be estrogen-dependent, such as ovarian cancer. Outside of its
direct proliferative effect in ER+ breast tumors, little is known about the effect of
estrogen signaling on the tumor microenvironment, despite normal cell ER positivity in a
variety of tumors. Using immunocompetent mouse models, we demonstrate that
iii

systemic estrogen levels have an important effect on antitumor immunity. Independent
of neoplastic cell signaling, estrogens promote tumor progression by directly and
indirectly suppressing antitumor T cell responses. Estrogen-driven decreases in
antitumor T cell effector activity correspond with a large, cell-intrinsic increase in
monocytic and granulocytic myeloid-derived suppressor cells (MDSCs). We show that
estrogen signaling increases responsiveness to tumor-initiated inflammatory signals to
augment STAT3 activation during myeloid cell differentiation. Estrogen increases the
expression of activating kinases, such as Jak2, in bone marrow progenitor cells thus
priming the host to respond to tumor-driven IL-6 by producing more MDSCs. Without
estrogen signaling, MDSC differentiation and suppressive activity is greatly diminished.
Therefore, estrogens are able to play an important role in potentiating a suppressive
ovarian tumor microenvironment. This work suggests that antiestrogens have clinical
potential in a wide variety of tumors, especially in combination with immunotherapies or
chemotherapies targeting pathways critical for MDSC differentiation.
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CHAPTER 1

GENERAL INTRODUCTION
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Ovarian cancer
In 2012, ovarian cancer was diagnosed worldwide in 238,700 women and was
responsible for 151,900 deaths (Torre et al. 2015). Although ovarian cancer is relatively
uncommon and only comprises 2.6% of cancer diagnoses among US women, at 5.1% it is
responsible for a disproportionate number of female cancer deaths (Siegel, Miller, and
Jemal 2016). Ovarian cancer is the fifth leading cause of cancer deaths among US
women and is the deadliest gynecological malignancy. Because currently there are no
consensus screening guidelines for early detection, ovarian cancer has been called the
“silent killer.” At diagnosis, 60% of ovarian cancers have already progressed to distant
disease, which carries a dismal five-year survival rate of 28% (Siegel, Miller, and Jemal
2016).
Treatment for ovarian cancer typically starts with surgery for staging and
cytoreduction. Standard staging includes total extrafascial hysterectomy with bilateral
salpingo-oophorectomy and dissection of pelvic and paraaortic lymph nodes (Mann,
Chalas, and Valea 2014). Typically, omantectomy and cytology of the diaphragm are
also performed for disease staging. Cytoreductive surgery is then performed to remove
all grossly visible tumor nodules found within the peritoneal cavity. In many cases,
cytoreductive surgery is suboptimal due to disease involvement of unresectable tissue,
such as bowel, or is limited by the patient’s ability to tolerate such an invasive surgery.
Additionally, surgery alone cannot remove micrometastases. Therefore, in addition to
surgery, patients are also given adjuvant chemotherapy. The most common first-line
regimen is a combination of platinum plus taxane therapies, such carboplatin plus
paclitaxel (Herzog and Armstrong 2016).
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As evinced by its five-year survival rate of 28%, despite surgery and
chemotherapy, most ovarian cancers with distant disease at diagnosis will recur and
ultimately result in death. Therefore, there is great need for a better understanding of the
biology of ovarian cancer to facilitate the development of new therapies. Of note, Zhang
et al. found that ovarian tumors with tumor-infiltrating lymphocytes correlate with
significantly increased survival (L. Zhang et al. 2003). This discovery suggests that the
tumor microenvironment plays a critical role in ovarian cancer progression, as has been
demonstrated in other cancers.

Composition of the tumor microenvironment
Cancers begin as neoplastic cells characterized by uncontrolled cell growth
following oncogenic transformation. Over time, neoplastic cells continue to proliferate
and become less differentiated, ultimately giving rise to carcinomas in situ. Upon
acquiring an invasive phenotype, such as via epithelial-mesenchymal transition (Ye and
Weinberg 2015), tumors are able to metastasize to distal locations, ultimately resulting in
death. It is now evident that the progression of tumors from benign neoplasias to
malignant, metastatic cancers depends on the accumulation of non-neoplastic, normal
cells comprising the tumor microenvironment and pre-metastatic niche (Figure 1.1)
(Sceneay, Smyth, and Möller 2013; Hanahan and Weinberg 2011).
Non-neoplastic cells in the tumor microenvironment include fibroblasts,
endothelial cells, pericytes, and leukocytes in addition to the normal, untransformed cells
from which neoplastic cells were originally derived. Each of these cell types is capable
of playing a critical role in primary tumor growth and metastasis. Fibroblasts provide
3

cytokines, extracellular matrix, and matrix metalloproteases that affect both neoplastic
and non-neoplastic cells within the tumor microenvironment (Kalluri and Zeisberg 2006).
For example, cancer-associated fibroblasts known as myofibroblasts secrete stromal cellderived factor 1 (SDF1) resulting in recruitment of endothelial cells and direct
stimulation of breast cancer cell proliferation (Orimo et al. 2005). Additionally, cancer
cell invasiveness is altered in response to different extracellular matrix components
produced by fibroblasts, such as collagen (Öhlund et al. 2013). Another key aspect of
growing tumors is recruitment of blood vessels composed of endothelial cells and
pericytes to provide the tumor with oxygen and nutrients as well as the removal of
potentially harmful metabolic byproducts. Additionally, blood (and lymphatic) vessels
provide tumors with routes to metastasize to distal locations. The initiation of tumor
angiogenesis, also known as the “angiogenic switch,” may occur at any tumor stage and
is characterized by aberrant vascular structure (Bergers and Benjamin 2003). Unlike
normal blood vessels, tumor blood vessels are disorganized, irregularly shaped, and can
have dead ends resulting in vascular leakage and a relatively hypoxic tumor
microenvironment. Targeting tumor vasculature, for example by pharmacological
inhibition of vascular endothelial growth factor receptor (VEGFR) (Batchelor et al. 2007)
or antibody-based blockade of VEGF (Burger et al. 2011), may impact tumor progression
and sequelae, such as swelling that may impinge on neighboring organs.
Understanding the tumor microenvironment is an active and diverse field of
interest resulting in the much needed development of novel therapies. However, perhaps
the most exciting and clinically relevant hallmark of the tumor microenvironment is the
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interaction between tumors and the immune system, as evidenced by Cancer
Immunotherapy being named Science’s “Breakthrough of the Year” in 2013.

Tumors and the immune system
Tumor-infiltrating leukocytes spontaneously recruited by tumors comprise the
most heterogeneous population of cells within the tumor-microenvironment. Tumor- and
normal neighboring cell-derived signals incited by growing tumors, such as damage
associated molecular patterns (DAMPs), initially recruit innate immune cells, such as
dendritic cells (DCs). Upon activation, DCs transit to lymphoid organs where they prime
adaptive immune cells, such as T cells, to respond to the tumor. Both lymphocytic and
myeloid cells are found within tumors and can have pro- or anti-tumor functions.
According to the “immunoediting hypothesis,” the interaction between the immune
system and tumors can progress through three stages: Elimination, Equilibrium, and
Escape (Dunn, Old, and Schreiber 2004; Mittal et al. 2014). Tumors may initiate at and
transition between any of these stages. During the “Elimination” stage, tumors
recognized by the immune system trigger a cytotoxic response that eradicates the tumor.
Evidence for the elimination stage was demonstrated in mice that spontaneously develop
B cell leukemias via tissue-specific overexpression of c-myc. In immunocompetent mice,
these leukemic cells are eliminated by approximately 6 weeks of age; however, mice
subjected to NK and T cell depletion fail to reject these spontaneous early cancer cells
(Croxford et al. 2013). If early tumors are not eliminated by the immune system, they
may graduate to the “Equilibrium” stage where, despite immune pressure, undetected
tumors are not rejected. Clinically, evidence of the equilibrium stage can be found in
5

immunosuppressed transplant patients who develop tumors in organs from
immunocompetent donors that were grossly normal at time of harvest (MacKie, Reid, and
Junor 2003). Evidence of the equilibrium stage was experimentally demonstrated using a
mouse model where previously undetected carcinogen-induced sarcomas were only able
to grow out when the mice were subjected to CD4, CD8, and Interferon-γ (IFN-γ)
depletion (Teng et al. 2012). Presumably, neoplastic cells were present but unable to
form palpable tumors in these mice prior to depletion, which would suggest that the
tumors were indeed in the equilibrium stage. If the immune system is incapable of
complete eradication, then tumors may proceed to the “Escape” stage of immunoediting.
At this point, tumors are able to avoid immune destruction, allowing for progressive
growth and clinical pathology. Mechanisms of tumor escape include strategies to reduce
immune recognition as well as tumor-driven immunosuppression. The relative
importance of each of these mechanisms likely varies according to tumor type. In highly
mutated tumors, such as malignant melanomas and carcinogen-induced preclinical
models, mutational neoantigens are targeted by the immune system (Gubin et al. 2015;
Robbins et al. 2013). In these tumors, loss of MHC (Angell et al. 2014) or loss of
antigenic epitopes (Sotillo et al. 2015) may result in tumor escape. Virtually all tumors
that have successfully avoided immune destruction do so at least in part by creating an
immunosuppressive microenvironment. Cancer cell-intrinsic mechanisms of suppression
include secretion of immunosuppressive cytokines, for example transforming growth
factor beta (TGF-β) (Stephen et al. 2014), and cancer cell surface expression of inhibitory
ligands, such as PD-L1 (Lyford-Pike et al. 2013). Tumors also recruit suppressive
leukocytes, such as tolerogenic dendritic cells (DCs) (Scarlett et al. 2012), myeloid6

derived suppressor cells (MDSCs) (Youn et al. 2008), and regulatory T cells (Tregs)
(Serrels et al. 2015).
Despite immune evasion being one of the hallmarks of growing cancers, evidence
suggests that the immune system is still capable of exerting antitumor pressure. For
example, increased T cell infiltration is a positive prognostic indicator in a variety of
tumors, indicating that the immune system is activated even in established tumors (L.
Zhang et al. 2003; Hwang et al. 2012). Additionally, the success of immune checkpoint
inhibitory therapies, for example anti-PD1 and anti-CTLA-4, demonstrates that tumors
spontaneously elicit protective immune reactions (Jensen et al. 2013; Akbay et al. 2013).
Tumor immunoediting is a dynamic and complex process, which can proceed in a
non-linear manner. To better understand the interaction between tumors and the immune
system, it is important to recognize that inflammation underlies the recruitment and
behavior of leukocytes within the tumor microenvironment.

Inflammation and cancer
Due to the continued presence of aberrant stromal cells such as myofibroblasts,
neovascularization, and infiltrating leukocytes, tumors have been described as “wounds
that never heal” (Dvorak 1986). As is the case in wound healing, inflammation is a major
characteristic of established tumors. Inflammation broadly describes the milieu of
cytokines and the cells they elicit within the tumor microenvironment that can have proor anti-tumor effects. Acute inflammation results in the recruitment of antitumor
cytotoxic innate and adaptive immune cells; however, if a tumor is not eradicated,
chronic inflammation provides pro-tumor signals, such as the accumulation of
7

immunosuppressive leukocytes. Many strategies have been employed to shift the balance
between pro- and anti-tumor inflammation (Coussens, Zitvogel, and Palucka 2013;
Cubillos-Ruiz et al. 2012; Scarlett et al. 2009).
One of the major players in tumor-associated inflammation are myeloid cells,
such as macrophages and dendritic cells (DCs). Under normal physiological conditions,
macrophages and DCs respond to pathogen- and damage-associated molecular patterns to
present antigen and activate adaptive immune cells. However, in numerous tumor
models, tumors drive aberrant myelopoiesis, resulting in the accumulation of tumorpromoting populations. For example, in an autochthonous model of ovarian cancer, early
stage DCs trigger a protective antitumor immune response dependent on CD8 T cells,
while late stage DCs suppress antitumor immunity (Scarlett et al. 2012). Tumorassociated macrophages (TAMs) also appear to have both anti- and pro-tumor
phenotypes, classified into the in vitro categories as either classical M1 or alternative M2
macrophages (Chanmee et al. 2014). M1 TAMs produce antitumor cytokines, such as
IL-12, while M2 TAMs support tumor survival by producing pro-tumor cytokines, such
as IL-10 and TGF-β, and expressing immunosuppressive enzymes, such as IDO and
arginase (Woo, Corrales, and Gajewski 2015; Parsa et al. 2012).
Similar to the dual potential of myeloid cells in tumor-associated inflammation, T
cells are also capable of serving as anti- or pro-tumor effectors. Th1 CD4 helper T cells
produce IFN-γ, which helps trigger CD8 cytotoxic T cell activation and primes cancer
cells for killing by up-regulating MHC-I (Angell et al. 2014). However, IFN-γ also
induces expression of PD-L1 providing tumors with the means to induce T cell
exhaustion (Lee et al. 2006). In addition to Th1, CD4 T cell polarization can result in
8

Th2 and regulatory T cells (Tregs), both of which accelerate malignant progression. Th2
cells produce cytokines, such as IL-4 that stimulate the differentiation of pro-tumor
macrophages (Q. Zhang et al. 2015). Tregs inhibit antitumor immune responses and are
often associated with worse clinical outcomes (Curiel et al. 2004). Tregs suppress
conventional T cell proliferation and effector function through a number of direct and
indirect mechanisms (Schmidt, Oberle, and Krammer 2012). Tregs can directly suppress
conventional T cells by producing suppressive cytokines and metabolites, such as IL-10,
IL-35, TGFβ, and adenosine (Collison et al. 2010; Mandapathil et al. 2010). Additionally
and controversially, Tregs express high levels of the IL-2 receptor CD25, which removes
IL-2 from the tumor microenvironment, thereby depriving conventional T cells of an
important survival/proliferation signal (Pandiyan et al. 2007). In addition, Tregs are
capable of indirectly suppressing conventional T cells by expressing high levels of
CTLA-4. CTLA-4 has a higher affinity for costimulatory molecules, such as CD80 and
CD86 expressed by antigen presenting cells compared to CD28. This allows for Tregs to
functionally reduce APC expression of CD80 and CD86, which impairs their ability to
activate conventional T cells (Cederbom, Hall, and Ivars 2000). Strategies to reduce
tumor progression by preventing Treg accumulation, for example by inhibiting
chemokine CCL5 tumor secretion (Serrels et al. 2015) and antibody depletion of CTLA4+ and OX40+ cells (Marabelle et al. 2013), demonstrate that Tregs can be potent
immunosuppressive players in the tumor microenvironment.
It is clear that the host inflammatory response to tumors is a major determinant of
the composition and function of the tumor microenvironment. Inflammation initially
triggers antitumor immune responses; however, chronic inflammation can have the
9

opposite effect and suppress antitumor immunity. Therefore, there is great interest in
further understanding factors that influence the host “macroenvironment.”
Endocrine signals are thought to impact inflammation, but have largely remained
unexplored in the context of the tumor microenvironment. In particular, estrogens are
known for their immunomodulatory effects and are thought to contribute to sex
differences in inflammation and autoimmune disease (Oertelt-Prigione 2012a; OerteltPrigione 2012b; Hughes and Choubey 2014). However, the primary interest in estrogens
with regard to cancer has focused on their neoplastic cell-intrinsic effects, such as their
ability to simulate estrogen receptor positive (ER+) breast cancer proliferation. To treat
such cancers, estrogen antagonists have been developed and are commonly used in the
clinic. Therefore, understanding the potential impact of estrogens on the tumor
microenvironment is a novel concept, which has immediate therapeutic potential in a
variety of tumors, including non-breast and ER negative cancers.

Estrogens and their receptors
Estrogens (estrone, E1; estradiol, E2; and estriol, E3) are steroid hormones
produced by the aromatization of androgens, which are metabolized from cholesterol
(Gruber et al. 2002). In premenopausal women, the most potent estrogen, E2, is
produced mainly by the ovaries. Despite being present at lower concentrations, estrogens
are also produced and have important biological functions in males and postmenopausal
women. Notably, adipose tissue expresses aromatase thus making it a site for peripheral
estrogen conversion. Individuals with large amounts of adipose tissue tend to have
higher levels of estrogens (Iyengar, Hudis, and Dannenberg 2015; Mauras et al. 2015),
10

which has been hypothesized to predispose them to certain estrogen-related diseases. For
example, obese individuals are at a higher risk of breast and endometrial cancers and
metabolic syndrome (Matic et al. 2013). Additionally, estrogen signaling can be
provided by environmental exposure to xenoestrogens, such as phytoestrogens present in
soy-based diets or endocrine-disrupting chemicals like bisphenol A, which is present in
plastic products (Katchy et al. 2014). In addition, estrogens can be further metabolized
into 2-hydroxyestrogens, 16α-hydroxyestrogens, and methoxylated estrogens, which are
also biologically active (Stubelius et al. 2014; Li et al. 2014). In vitro, estrogens are
ubiquitously found in typical cell culture media containing fetal bovine serum and phenol
red, which is estrogenic (Furuya et al. 1989; Berthois, Katzenellenbogen, and
Katzenellenbogen 1986).
Estrogens signal through G protein-coupled estrogen receptor 1 (GPER) and,
predominantly, the nuclear receptors, estrogen receptor α (ERα) and β (ERβ). GPER
activation by ligand binding results in rapid non-genomic signaling, similar to other G
protein-coupled receptors. ERα and β are comprised of an N-terminal domain containing
an activation function domain (AF1), a highly conserved DNA binding domain, and a
ligand binding domain, which contains a second activation function domain (AF2)
(Kumar et al. 2011). Upon ligand binding, ERs translocate into the nucleus where they
dimerize and bind estrogen response elements (EREs; 5’-GGTCAnnnTGACC-3’), thus
mediating transcription via AF1 and AF2 domain interaction with coactivators,
corepressors, and general transcriptional machinery. Importantly, AF1 is capable of
transcriptional activation independent of ligand binding. On the other hand, AF2 activity
requires ligand binding (Arnal et al. 2013). Therefore, in addition to classical ER-E2
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binding and activation, ERs are also capable of ligand-independent transactivation by
binding to other transcription factors, such as X box-binding protein 1 (XBP-1) (Ding et
al. 2003). Additionally, ERs are capable of forming complexes with other transcription
factors, such as AP-1, SP1, and NF-κB. The DNA binding domains of these transcription
factors tether ERs to DNA resulting in estrogen regulation of genes that lack promoter
EREs (Candelaria, Liu, and Lin 2013).
Expression of estrogen receptors is pervasive, dynamic, and varies by receptor.
According to the Human Protein Atlas (www.proteinatlas.org), ERα is expressed most
prominently by the female reproductive system (cervical, vaginal, endometrial, fallopian
tube, breast, and ovarian tissue) and at lower levels in other tissues; ERβ expression is
more varied, but highest in testis, ovary, and adrenal gland; and GPER is expressed in
nearly all tissues (Uhlén et al. 2015). Notably, ERα, ERβ, and GPER are expressed by
lymphoid and myeloid leukocytes (Yakimchuk, Jondal, and Okret 2013; Brunsing,
Owens, and Prossnitz 2013). ER expression is dynamic and can be regulated by the
menstrual cycle (Slayden and Brenner 2004) or by other factors. For example, ERα is
up-regulated by male and female macrophages upon lipopolysaccharide (LPS) activation;
however, this increase is significantly more pronounced in females compared to males
(Campesi et al. 2016). Additionally, the ratio of ERα to ERβ expression appears to
decrease in cells found in inflammatory and hypoxic settings (Straub 2007).
Estrogens are a diverse class of molecules with the potential to affect a wide
variety of target cells and biological systems through the near ubiquitous expression of
ERα, ERβ, and GPER.
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Physiological roles of estrogens
Estrogens underlie a number of important physiological processes (Gruber et al.
2002). Predominantly, estrogens are known for their role in reproduction. Estrogen
signaling is required for normal sexual development, as female mice lacking ERα are
completely infertile, and the fertility of male ERα knockout mice is greatly reduced
(Lubahn et al. 1993). Female ERβ KO mice show similar, albeit less severe, defects in
fertility (Walker and Korach 2004). Female mice that lack both ERα and ERβ appear to
undergo partial sex reversal resulting in the formation of ovarian follicles that resemble
seminiferous tubules of testis (Couse et al. 1999).
The diverse biological effects of estrogens are illustrated well in premenopausal
women, in whom estrogen levels vary according to the menstrual cycle. During the
follicular phase, the pituitary secretes increasing concentrations of follicle-stimulating
hormone (FSH) to stimulate the development of several follicles, one of which continues
to develop and produce E2. Estrogen levels produced by follicular granulosa and theca
cells continue to increase and peak in the preovulatory phase. This increase stimulates
endometrial cell proliferation, resulting in uterine wall thickening, and, upon reaching a
certain threshold, triggers a pituitary surge in luteinizing hormone, which in turn initiates
ovulation. During the ovulatory phase, the follicle releases its egg, forms the corpus
luteum, and E2 levels decrease. In the subsequent luteal phase, the corpus luteum
produces progesterone and resumes E2 production. E2, now in combination with
progesterone, continues to induce uterine wall thickening. If fertilization does not occur,
increasing amounts of estrogen and progesterone suppress FSH and LH, resulting in
atrophy of the corpus luteum. Without the corpus luteum, estrogen and progesterone
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levels drop resulting in shedding of the endometrial lining, and the menstrual cycle
restarts. If fertilization does occur, the developing blastocyst produces human chorionic
gonadotropin (hCG), which sustains the corpus luteum and estrogen production. During
pregnancy, the placenta and fetus produce large amounts of estrogen, which supports
fetal development and prepares the mother for breastfeeding by stimulating proliferation
of ductal epithelial cells.
In addition to reproduction, estrogens play a prominent role in other physiological
systems, such as bone metabolism, wound healing, and angiogenesis. In bone
metabolism, osteoporosis is caused by estrogen deficiency, which can occur during
menopause and be treated with estrogen replacement therapy (Gruber et al. 2002).
Estrogens control the balance between osteoblasts, responsible for bone formation, and
osteoclasts, responsible for bone resorption. In estrogen-deficient ovariectomized mice,
bone remodeling skews in favor of osteoclasts through several mechanisms in which T
cell and osteoblast cytokine production are altered, resulting in increased osteoclast
differentiation (Pacifici 2008). In cutaneous wound healing, estrogens appear to have a
protective effect, as estrogen treatment increases wound healing in postmenopausal
women and ovariectomized mice (Mukai et al. 2014). Additionally, studies using a
knockout mouse model demonstrate that cell-intrinsic ERα signaling is required for
macrophages to acquire a pro-healing phenotype (Campbell et al. 2014). Additionally,
myofibroblasts, which promote wound healing, express and are regulated by ERα (Yeh et
al. 2016). In angiogenesis, estrogen promotes the mobilization of bone marrow-derived
endothelial cells, resulting in neovascularization. This process requires up-regulation of
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hypoxia-induced factor 1α (HIF-1α) in epithelial cells resulting in VEGF production
(George et al. 2012).
Estrogens perform a number of important biological processes, such as
reproductive development, bone metabolism, wound healing, and angiogenesis. It is
important to note that these processes are often co-opted by tumors. ER+ breast tumors
proliferate in response to E2. Bone metabolism affects the microenvironment of bone
metastasis and potentially impacts the host hematopoietic response to the tumor (Inoue et
al. 2007; Sceneay, Smyth, and Möller 2013). Macrophages, fibroblasts, and endothelial
cells, crucial for wound healing and angiogenesis, are also found in the tumor
microenvironment. As discussed previously, inflammation underlies much of the host
response to tumors, such as antitumor immunity. In addition to the above mentioned
systems, estrogen has potent inflammatory effects, thus implicating estrogen as a key
mediator of the tumor microenvironment.

Estrogen and inflammation
Estrogens affect the differentiation and function of a wide variety of leukocytes,
ultimately resulting in pro- and anti-inflammatory effects (Table 1.1). The dual nature of
estrogens in inflammation is demonstrated by their effects on various inflammatory
autoimmune diseases. As an aside, autoimmune diseases are generally more prevalent in
women compared to men, with estrogens thought to be a key factor underlying this
sexual dimorphism (Pennell, Galligan, and Fish 2012; Khan and Ansar Ahmed 2015). In
systemic lupus erythematous (SLE), which is considered to be a Th2-driven autoimmune
disease due to the presence of auto-antibodies, estrogens appear to be an exacerbating
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factor (Jiang et al. 2007). High levels of estrogen, such as those achieved in pregnancy,
can trigger SLE flare-ups by increasing Th2 CD4 helper T cell polarization. Th2 cells
support B cells, which produce pathogenic auto-antibodies (Doria et al. 2006). On the
other hand, multiple sclerosis and rheumatoid arthritis, which are considered to be a
Th1/17-driven diseases are ameliorated by increased ERα-driven suppression of Th1 and
Th17 CD4 polarization (Lélu et al. 2011).
Similar to autoimmunity and reminiscent of tumors, pregnancy is considered an
inflammatory state due to the presence of non-self, fetal antigens. High estrogens levels,
in addition to supporting fetal development, are believed to be important in maintaining
feto-maternal tolerance. During pregnancy, estrogens skew CD4 helper T cell
polarization from a Th1 towards a Th2 phenotype (Robinson and Klein 2012).
Additionally, pregnancy levels of E2 favor CD4 Treg differentiation, which may be
important in suppressing maternal immune responses against the fetus (Haghmorad et al.
2014).
The specific effect of E2 on immune cell subsets is further complicated by its
dependence on a combination of additional cytokine signals. Therefore, depending on
additional cytokines, E2 may have very different effects on the same cells. For example,
myeloid progenitor cells treated with GM-CSF or Flt3 ligand differentiate into dendritic
cells. Combining GM-CSF treatment with E2 increases DC differentiation; however,
combining Flt3 ligand treatment with E2 actually decreases the yield of DCs (Carreras et
al. 2008).
Estrogens influence the response of leukocytes to inflammatory signals, which
can either increase or dampen ongoing inflammation. Therefore, estrogen levels are
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potentially an important factor to consider when determining immune responses induced
by tumor-driven inflammation.

Estrogen and the tumor microenvironment
The prevalence of certain cancers varies according to sex, which suggests that
differences in sex hormones, such as estrogens, may play a role in tumorigenesis. For
example, hepatocellular carcinoma is more prevalent in men as well as in a carcinogeninduced mouse model. Here, liver macrophages were found to respond to carcinogeninduced injury by releasing IL-6, which increases tumorigenesis. In females, estrogen
suppresses IL-6 release resulting in lower rates of hepatocellular carcinoma (Naugler et
al. 2007).
In addition to tumorigenesis, estrogens are capable of contributing to tumor
progression independent of cancer cell-intrinsic effects. E2 treatment of
immunocompromised mice bearing patient-derived ER- xenografts resulted in ERαdependent, cell-intrinsic mobilization of macrophages, which was associated with
increased vascularization (Iyer et al. 2012).

Estrogen and MDSCs
Myeloid-derived suppressor cells (MDSCs) are potent tumor-promoting cells.
MDSCs originate from bone marrow in response to chronic inflammatory cytokines, such
as granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-6 (Marigo et al.
2010). MDSCs are truly pathological cells that do not differentiate under normal
physiological conditions. Instead, they differentiate in response to tumor-associated
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inflammation via a mechanism requiring the loss of retinoblastoma protein (Rb1) (Youn
et al. 2013). In addition to suppressing immune responses (Condamine et al. 2014), these
cells are capable of supporting tumor progression by regulating tumor cell division,
invasion, and vasculogenesis (Talmadge and Gabrilovich 2013).
There is now emerging evidence linking estrogen to MDSCs in chronic
inflammatory states. Notably, pregnancy, where estrogen levels are the highest, is
associated with increased numbers of MDSCs (Köstlin et al. 2014), which may help
suppress maternal rejection of the fetus (Pan et al. 2016). Additionally, in pregnancy,
hosts are more susceptible to tumor metastasis, which may be the result of increased
MDSC accumulation in metastatic tissue (Mauti et al. 2011). Estrogens also appear to be
associated with increased MDSCs in the peripheral blood of lupus patients as wells as in
mice treated with TNF-α suggesting that estrogens increase MDSC accumulation in
individuals with chronic inflammation (Dong et al. 2015).
Despite estrogens and MDSCs being common mediators of inflammation in a
variety of pathological settings and compelling evidence linking the two, currently there
have been no studies expressly demonstrating that in tumors, estrogens influence the
accumulation of MDSCs, which ultimately impacts tumor progression.

Hypothesis
I hypothesize that estrogens, in combination with tumor-associated inflammation,
directly and indirectly suppress antitumor T cell responses by skewing CD4 T cell
differentiation and by increasing MDSC accumulation (Figure 1.2).
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Figures
Figure 1.1

Figure 1.1: Hallmarks of cancer
Tumors are a combination of immortalized neoplastic cells that continue to proliferate
regardless of environmental cues and normal cells recruited in response to the tumor.
The host’s systemic response to developing tumors is complex with pro- and anti-tumor
effects. Adapted from Hanahan and Weinberg (2011).
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Table 1.1
B cells

T cells

High
(Pregnancy)
> 7000 ng/mL

↑ Antibodies

↓ TNF
↑ IL-4
↑ IFN-γ
↑ IL-10
↑ TGFβ

Low
(Menopause)
< 10 pg/mL

↑ Antibodies

↑ TNF
↑ IFN-γ

Macrophages
/ DCs
↓ TNF
↓ IL-6
↓ IL-1β
↑ IL-10
↑ IL-1β

NK Cells

Fibroblasts

↓ Activity ↓ MMP-1/3
↓ MCP-1
↑ IL-6
↑ bFGF
↑ TIMP
↑ OPG
↑ Activity

Table 1.1: Pro- and anti-inflammatory effects of estradiol
Depending on concentration and cell type, estradiol (E2) can result in the secretion of
pro- or anti-inflammatory cytokines (Straub 2007).
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Figure 1.2

Figure 1.2: Hypothesis for the effects of E2 on the ovarian tumor microenvironment
Estrogens, which may originate from endogenous or external sources, augment the
response of BM to tumor-initiated inflammation (i.e., cytokines). This results in
increased mobilization of MDSCs that impair antitumor immune responses, further
accelerating malignant progression.
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CHAPTER 2

MATERIALS AND METHODS
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Mice
Female 5-8 week old wild type (WT) C57BL/6 and congenic Ly5.1 mice were
purchased from the Charles River Frederick facility. Rag1 knockout and Esr1 knockout
(ERα KO) were originally purchased from The Jackson Laboratory and bred in-house.
ERα genotyping was performed by digesting tail clippings and PCR (Table 2.1). All
mice were maintained in pathogen-free barrier facilities and fed ad libitum a diet
containing soy bean meal (Pico-vac Lab Mouse Diet 20, LabDiet). All experiments were
conducted with the approval of the Wistar Institute Institutional Animal Care and Use
Committee.

In vivo Estrogen Depletion
Estrogen depletion was achieved by ovariectomization (OVX) performed at 5
weeks of age. Mice were prepared for surgery by anesthetization via i.p. injection of a
mix of ketamine (80-100 mg/kg) and xylazine (8-10 mg/kg) in sterile saline, shaving, and
the skin sterilization using betadine and ethanol. Meloxicam (1 mg/kg) and Buprenex (2
mg/kg) were injected s.q. for pain management. Small incisions were then made in the
peritoneal wall allowing exteriorization of ovaries. Fallopian tubes were ligated shut
approximately 3 mm proximal to ovaries prior to ovarian excision. Following removal of
ovaries, the remaining fallopian tubes were returned to the peritoneal cavity, and
peritoneal wall incisions were sutured shut. Mice were given additional doses of
Meloxicam and Buprenex for pain management and allowed to recover for two weeks.
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In vivo Estrogen Augmentation
For estrogen augmentation, mice were treated with vehicle (0.1% ethanol) or 10
μM estradiol (USP grade, Sigma) drinking water refreshed every 3-4 days in lightprotective amber bottles.

Cell Lines
The mouse ovarian epithelial cell line, ID8, was provided by K. Roby
(Department of Anatomy and Cell Biology, University of Kansas) (Roby et al. 2000) and
retrovirally transduced to express Defb29 and Vegf-a (Conejo-Garcia et al. 2004). MCF7, MDA-MB-231, LLC1, and B16.F10 cells were obtained from American Type Culture
Collection.

In vivo Tumor Challenge
Peritoneal tumors were initiated in mice by injecting 3X106 ID8-Defb29/Vegf-a
cells intraperitoneal (i.p.). Intraperitoneal cells were harvested from tumor-bearing mice
by flushing the peritoneal cavity with PBS. Cells were maintained in vitro at 37° C, 5%
CO2 by culturing in RPMI+10% FBS or steroid free media (SFR10), which was
comprised of phenol red-free RPMI+10% charcoal-stripped FBS (Gibco).

In vitro Estrogen Treatment
Cells were treated in vitro with vehicle (0.1% DMSO) or varying concentrations
of estradiol, fulvestrant, or Methylpiperidino pyrazole (MPP) purchased from Cayman
Chemical. Cell line proliferation was determined by MTS assay (Promega), and
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increased/decreased proliferation relative to vehicle was calculated from absorbance
readings at 490 nm at 30 minutes. For E2-induced proliferation experiments using
SFR10, cells were incubated in SFR10 2 days prior to 5-day treatment.

Mixed BM Chimeras
To generate mixed BM chimeras, nucleated BM cells were collected from adult
age-matched CD45.1 (congenic) WT or CD45.2 Esr1-/- donor mice. Mice were
reconstituted with 1-5X106 total cells containing a 1:1 mix of WT and KO cells via retroorbital injection into adult recipients approximately 5 hours after receiving a lethal dose
(~1100 rad) of γ-radiation. Mixed chimeras were analyzed after 6-8 weeks as indicated.

Human Samples
Human ovarian carcinoma tissues were procured under a protocol approved by
the Committee for the Protection of Human Subjects at Dartmouth-Hitchcock Medical
Center (#17702) and under a protocol approved by the Institutional Review Board at
Christiana Care Health System (#32214) and the Institutional Review Board of the Wistar
Institute (#21212263). Bone marrow (BM) was obtained from Stage I-II lung cancer
patients scheduled for surgical resection at the Hospital of the University of Pennsylvania
and The Philadelphia Veterans Affairs Medical with approval from respective
Institutional Review Boards. All patients selected for entry into the study met the
following criteria: (i) histologically confirmed pulmonary squamous cell carcinoma
(SCC) or adenocarcinoma (AC), (ii) no prior chemotherapy or radiation therapy within
two years, and (iii) no other active malignancy. BM cell suspension was obtained from
25

rib fragments that were removed from patients as part of their lung cancer surgery.
Informed consent was obtained from all subjects.

Immunohistochemistry
Frozen ovarian tissue sections were thawed and allowed to dry overnight before
being fixed with chilled acetone for 10 minutes. After washing with PBS, endogenous
peroxidases were quenched by adding 0.3% H2O2 for 10 minutes at room temperature.
Following a second wash, the slides were then blocked using 500 µg/mL human γglobulin in PBS for 30 minutes at room temperature. Slides were then stained for ERα
using mouse anti-ERα primary antibody 6F11 (Table 2.2) diluted 1:100 in PBS and
incubated for 1 hour at room temperature. Following another PBS wash, slides were
incubated for 30 minutes at room temperature with 7.5 µg/mL biotinylated anti-mouse
IgG secondary antibody diluted in PBS+3% goat serum. To develop, ABC complex
(Vector Laboratories) was added to the samples, incubated for 30 minutes at room
temperature, washed, and then treated with colorigenic DAB substrate. Subsequently,
nuclei were counterstained using hematoxylin. Following dehydration, slides were
mounted using Permount and visualized via bright field microscopy (Nikon E600 Upright
Microscope).

Flow Cytometry
Flow cytometry was performed by staining mouse cells with Zombie Yellow
viability dye (Biolegend #423103), blocking with anti-CD16/32 (2.4G2 cell supernatant),
and staining for 30 min at 4° C with fluorochrome-conjugated anti-mouse antibodies
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purchased from Biolegend or Tonbo Biosciences (Table 2.2). Similarly, human samples
were stained with Zombie Yellow, blocked with 0.5% FBS + 3 mg/mL human gamma
globulin, and stained for 30 min at 4° C with fluorochrome-conjected anti-human
antibodies (Table 2.2). Samples were subsequently sorted using a FACSAria II or run
using an LSRII and analyzed using FlowJo.

ELISpot
Dendritic cells (BMDCs) were differentiated by culturing WT mouse bone
marrow for 7 days with 20 ng/mL GM-CSF (Peprotech 315-03), refreshed every 3 days.
BMDCs were subsequently primed with tumor antigen by pulsing for 24 hours with
irradiated (100 Gy+30 minutes UV) ID8-Defb29/Vegf-a cells at a ratio of 10 BMDCs to 1
tumor cell. ELISpot assay was performed by stimulating 1X105 T cells FACS-isolated
from peritoneal wash with 1X104 antigen-primed BMDCs in a 96-well filter plate
(Millipore MSIPS4510) coated with IFN-γ capture antibody according to manufacturer’s
guidelines (eBioscience 88-3784-88). Following incubation at 37° C, 5% CO2 for 48
hours, wells were treated overnight at 4° C with biotinylated IFN-γ detection antibody
followed by 2 hour room temperature incubation with Avidin-AP (R&D Systems
SEL002). Positive spots were then developed using BCIP-NBT substrate (R&D Systems
SEL002).

Adoptive T Cell Transfer
Naïve T cells were harvested from spleens of WT or ERα KO mice via RBC lysis
followed by negative selection of B220+, CD16/32+, CD11b+ and MHC-II+ cells using
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anti-rat IgG magnetic beads (Thermo 11035) conjugated to rat IgG antibodies derived
from bioreactor hybridoma cultures (Table 2.2). T cells were then primed for 5 days
with BMDCs pulsed with irradiated tumor cells (see above) and supplemented with 10
U/mL IL-2 + 1 ng/mL IL-7 (Peprotech), as reported (Y. C. Nesbeth et al. 2010). A total
of 1X106 primed T cells per mouse was injected i.p. at 7 and 14 days post tumor
injection.

Bone Marrow-Derived MDSC Cultures
Mouse MDSCs were expanded from WT mouse bone marrow harvested by
flushing tibias and femurs with media. Following red blood cell lysis, 2.5X106 cells were
cultured in 10 mL of RPMI+10% FBS augmented with recombinant mouse 40 ng/mL
GM-CSF+40 ng/mL IL-6 (Peprotech) and incubated at 37°C, 5% CO2 3 or 6 days.
Vehicle, estradiol, or methylpiperidino pyrazole (MPP) treatments were added as
described above. For 6 day cultures, cytokines and estrogen treatments were refreshed on
day 3. Following incubation, floating and adherent cells were collected, and M-MDSCs
and G-MDSCs were isolated via Miltenyi MDSC purification kit (Miltenyi 130-094-538)
according to manufacturer’s protocol for further analysis. Human MDSCs were
expanded from human lung cancer patient bone marrow acquired as single cell
suspensions (see above). Briefly, 2X106 cells were cultured in 3 mL of IMDM+15%
FBS supplemented with recombinant human 40 ng/mL GM-CSF+40 ng/mL IL6
(Peprotech) and treated with Vehicle, 2µM, or 10µM MPP (see above) for 4 days. Cells
were subsequently harvested and analyzed by flow cytometry.
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MDSC Suppression Assay
Naïve WT T cells were purified from spleens as described above and labeled with
the proliferation tracker CellTrace Violet according to manufacturer protocol (Molecular
Probes). T cell proliferation was stimulated by adding anti-CD3/CD28 mouse T-activator
beads (Thermo) at a 1:1 T cell to bead ratio according to manufacturer protocol. T cells
(2X105) were subsequently co-cultured with MDSC at 1:4, 1:8, or 1:16 MDSC to T cell
ratios in 200 µL R10 (containing 2-ME) and incubated for 3 days prior to flow cytometric
analysis.

Western Blot
Cells were lysed in RIPA buffer (Thermo 89900) supplemented with a cocktail of
protease inhibitors and phosphatase inhibitors (Thermo 78446), and Na3VO4 according to
manufacturer protocol. Protein quantification was determined via BCA assay, and 5-20
µg protein was run on TGX 4-15% gradient gels (Bio-Rad 4561083). Following transfer,
polyvinylidene fluoride (PVDF) membranes were blocked with 5% bovine serum
albumin in TBS+0.05% Tween-20. Primary antibodies were added to membranes and
incubated overnight with gentle agitation. Following secondary staining with HRPconjugated anti-mouse or rabbit IgG, membranes were developed using ECL prime (GE
Healthcare).

Quantitative Real Time PCR
Cells were lysed in Trizol buffer and RNA was subsequently purified using the
RNEasy Plus Kit (QIAGEN). Reverse transcription was carried out using the High29

Capacity Reverse Transcription Kit (Applied Biosystems). The resulting cDNA was then
used for real time PCR using Power SYBR Green (Applied Biosystems) and 500 nM
primers (Table 2.1). ABI 7500 Fast Sequence Detection Software (Applied Biosystems)
was used to quantify gene expression.

Statistics
Significant differences in survival between experimental groups were determined
by Kaplan-Meier Log-rank testing with a p-value < 0.05 deemed significant. To
determine whether the means of two groups (e.g., tumor volumes) differed significantly,
both groups were first tested for Gaussian distribution using the Kolmogorov-Smirnov
test. If both populations were found to be normal, then unpaired two-tailed T-tests were
used to calculate a p-value. If at least one population was determined to not be normal,
then Mann-Whitney tests were used. As before, a p-value < 0.05 was deemed significant.
All calculations were performed using GraphPad Prism.
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Tables
Table 2.1
Application

Target

Primer Sequences

Genotyping ERα WT allele (mouse) 5’-GGGGAGCCAGTCTGTAACTC-3’
5’-CTAGGCGACACGCTGTTGAG-3’
ERα KO allele (mouse) 5’-TTCCACATACACTTCATTCTC A-3’
5’-ACTGGCCTCAAACACCTG-3’
qPCR

Esr1 (human)

5’- CCACTCAACAGCGTGTCTC-3’
5’- GGCAGATTCCATAGCCATAC-3’

Gapdh (mouse/human)

5’- CCTGCACCACCAACTGCTTA-3’
5’- AGTGATGGCATGGACTGTGGT-3’

Stat3 (mouse)

5’- GGGTCTGAAGTTGAGATTCTGCT3’
5’-GACTGATGAAGAGCTGGCTGACT3’

Tbp (mouse)

5’- CACCCCCTTGTACCCTTCAC-3’
5’- CAGTTGTCCGTGGCTCTCTT-3’

Jak2 (mouse)

5’- GTGTCGCCGGCCAATGTTC-3’
5’- CACAGGCGTAATACCACAAGC-3’

Table 2.1: Primers used
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Table 2.2
Application

Target

Clone

Vendor

Flow Cytometry

CD45 (mouse)

30-F11

Tonbo

CD45.1 (mouse)

A20

Biolegend

CD45.2 (mouse)

104

Biolegend

CD4 (mouse)

GK1.5

Tonbo

CD8b (mouse)

YTS156.7.7

Biolegend

CD11b (mouse)

M1/70

Biolegend

MHC-II (I-A/I-E) (mouse) M5/114.15.2

T cell Isolation

Biolegend

CD11c (mouse)

N418

Tonbo

Ly6G (mouse)

1A8

Biolegend

Ly6C (mouse)

HK1.4

Biolegend

Gr-1 (mouse)

RB6-8C5

Biolegend

CD126 (mouse)

D7715A7

Biolegend

CD130 (mouse)

KGP130

Biolegend

CD44 (mouse)

IM7

Tonbo

CD69 (mouse)

H1.2F3

Biolegend

CD45 (human)

HI30

Tonbo

CD11b (human)

ICRF44

Biolegend

CD33 (human)

WM53

Biolegend

HLA-DR (human)

L243

Biolegend

CD14 (human)

HCD14

Biolegend

CD15 (human)

HI98

Bio

CD11b (mouse)

M1/70

BioXcell

MHC-II (mouse)

M5/114

n/a

B220 (mouse)

RA3

n/a
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CD16/32 (mouse)

2.4G2

n/a

Stat3

124H6

Cell Signaling

Phospho-Stat3 (Tyr705)

D3A7

Cell Signaling

Jak2

D2E12

Cell Signaling

ERα

TE111.5D11

Thermo

Β-Actin

AC-15

Sigma

Immunohistochemistry

ERα (human)

6F11

Thermo

In vivo MDSC depletion

Gr-1

RB6-8C5

Bio X Cell

Irrelevant IgG

LTF-2

Bio X Cell

Western Blot

Table 2.2: Antibodies used
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CHAPTER 3

ESTROGENS SUPPRESS ANTITUMOR IMMUNITY BY INCREASING
THE ACCUMULATION OF MYELOID-DERIVED SUPPRESSOR CELLS
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Abstract
The role of estrogens in antitumor immunity remains poorly understood. Here we
show that estrogen signaling accelerates the progression of different estrogen insensitive
tumor models by contributing to deregulated myelopoiesis. Estrogens drive the
mobilization of Myeloid-derived Suppressor Cells (MDSCs) and enhance their intrinsic
immunosuppressive activity. Differences in tumor growth were dependent on blunted
antitumor immunity and, correspondingly, disappeared in immunodeficient hosts.
Mechanistically, estrogen receptor alpha augmented the JAK-STAT3 pathway in human
and mouse bone marrow myeloid precursors by up-regulating JAK2 and, subsequently,
enhancing IL-6-driven overexpression of total STAT3. Therefore, estrogen signaling is a
crucial mechanism underlying pathological myelopoiesis in cancer. Our work suggests
that new antiestrogen drugs that have no agonistic effects may have benefits in a wide
range of cancers, independently of the expression of estrogen receptors in tumor cells,
and may synergize with immunotherapies to significantly extend survival.
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Introduction
Estrogens are pleiotropic steroid hormones known to influence many biological
processes that ultimately affect homeostasis, such as development and metabolism.
Estrogens bind to two high-affinity receptors (ERα and β) that recognize estrogen
response elements with different affinities and are differentially expressed in multiple
tissues. Due to their pathogenic role in accelerated malignant progression, ER+ breast
cancers have been commonly treated with tamoxifen. Tamoxifen, however, has mixed
antagonist/agonist effect on Estrogen Receptors (ERs), depending on the cell type (Gallo
and Kaufman 1997). Correspondingly, alternative interventions are currently evolving as
results from clinical testing emerge (Sini et al. 2016). In contrast to breast cancer,
antiestrogen therapies have proven to be effective in only some ovarian cancer patients
(Hasan et al. 2005; del Carmen et al. 2003; Smyth et al. 2007; Argenta et al. 2009;
Bowman et al. 2002). However, these studies exclusively focused on ovarian cancer
patients with ER+ tumors, which represent 31% for ERα and 60% for ERβ. These studies
therefore do not provide any insight into the effects of estrogen activity on non-tumor
cells within the ovarian tumor microenvironment. Additionally, ERβ may actually
provide anti-proliferative signaling in ovarian cancer (Bossard et al. 2012).
The tumor microenvironment plays a critical role in determining malignant
progression as well as response to various therapies. In particular, it is becoming evident
that tumors elicit immune responses that ultimately impact survival. In ovarian cancer,
for instance, the presence of tumor-infiltrating lymphocytes is a major positive prognostic
indicator of tumor survival (L. Zhang et al. 2003), and multiple T cell inhibitory
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pathways have been identified (Stephen et al. 2014; Cubillos-Ruiz et al. 2009; CubillosRuiz et al. 2010).
In addition to tumor cells, both ERs are expressed by most immune cell types,
including T cells, B cells and NK cells, in which ERα46 is the predominant isoform
(Pierdominici et al. 2010). Correspondingly, estrogens influence helper CD4 T cell
differentiation favoring humoral Th2 over cell-mediated Th1 responses (Salem 2004).
Women have higher levels of estrogen than men, which may contribute to differences in
the incidence of certain autoimmune diseases. Most importantly, various cancers, such as
colorectal, lymphoma, and hepatocellular cancer, exhibit sex biases that are at least partly
explained by hormonal differences. Obesity, which is associated with increased
adipocyte production of estrogens, is also a risk factor for a number of cancers. Changes
in estrogen levels in women caused by menstruation, menopause, and pregnancy are
associated with changes in the immune system, which could ultimately affect disease
susceptibility. For example, during the menstrual cycle the number of Tregs increases
coinciding with increased estrogen levels during the follicular phase (Oertelt-Prigione
2012a). Importantly, women given hormone replacement therapy have a significantly
increased risk of developing and dying from ovarian cancer (Beral et al. 2007). Despite
growing evidence implicating estrogen as a fundamental mediator of inflammation,
currently little is known about its potential role in antitumor immune responses and the
overall estrogen-responsive tumor microenvironment.
Factors that characterize tumor-associated inflammation, such as IL-6, induce
aberrant myelopoiesis in solid tumors, which fuels malignant progression in part by
generating immunosuppressive myeloid cell populations (Gabrilovich, Ostrand37

Rosenberg, and Bronte 2012). In ovarian cancer, deregulated myelopoiesis results in the
mobilization of Myeloid-Derived Suppressor Cells (MDSCs) from the bone marrow
(Rutkowski et al. 2015) and, eventually, the accumulation of tumor-promoting
inflammatory Dendritic Cells (DCs) with immunosuppressive activity in solid tumors
(Scarlett et al. 2012; Tesone et al. 2016). Additionally, canonical macrophages build up
in tumor ascites (Scarlett et al. 2012; Huarte et al. 2008). Although all of these cell types
express at least ERα and are influenced by estrogen signaling (Kovats 2012; Kovats
2015; Pan et al. 2016), the impact of estrogens on antitumor immunity remains elusive.
Here, we show that estrogens, independently of the sensitivity of tumor cells to estrogen
signaling, are a crucial mechanism underlying pathological myelopoiesis in ovarian
cancer. We report that estrogens drive MDSC mobilization and augment their
immunosuppressive activity, which directly facilitates malignant progression. Our data
provide mechanistic insight into how the augmented estrogenic activity observed in
BRCA1 mutation carriers (Widschwendter et al. 2013) may contribute to breast cancer
progression. Furthermore, this work provides a rationale for blocking estrogen signals to
boost the effectiveness of anti-cancer immunotherapies.
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Results
Tumor cell-extrinsic estrogen signaling impairs protective immunity against ovarian
cancer
Nuclear expression of ERs specifically in neoplastic cells has been identified in
human ovarian carcinomas of all histological subtypes, with strong signal in ~60% of
high-grade serous tumors (Sieh et al. 2013). ERα is the predominant estrogen receptor in
at least mouse hematopoietic cells (Pierdominici et al. 2010). To define the expression of
ERα in human ovarian cancer-infiltrating leukocytes, we performed
immunohistochemical analysis on 54 serous ovarian carcinomas. Supporting previous
reports, we found positive staining in tumor cells in ~35% of tumors (Figure 3.1A, left).
In addition, we identified a second class of ovarian tumors in which ERα expression was
confined to individual cells in the stroma (Figure 3.1A, right). To confirm that
hematopoietic cells at tumor beds indeed express ERα, we sorted (CD45+) cells from 7
different dissociated human ovarian tumors. As shown in Figure 3.1B, both tumorinfiltrating (CD11b+) myeloid cells and (CD11b-) non-myeloid leukocytes express ERα.
In addition, both myeloid and non-myeloid cells sorted from the bone marrow of a cancer
patient were also ERα+, suggesting that in addition to potentially having tumor cellintrinsic effects, estrogens may also play wider a role in shaping the ovarian tumor
immune-environment. To determine the role of estrogen signaling in tumor-promoting
inflammation or antitumor immunity, we used a preclinical model of aggressive ovarian
cancer in which syngeneic epithelial ovarian tumor cells (ID8-Defb29/Vegf-a) develop
intraperitoneal tumors and ascites that recapitulate the inflammatory microenvironment
of metastasized human ovarian tumors (Stephen et al. 2014; Rutkowski et al. 2015;
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Tesone et al. 2016; Conejo-Garcia et al. 2004). Importantly, no ERα was detected in
these cells, unlike tumor-associated myeloid cells (Figure 3.1C). Most importantly, ID8Defb29/Vegf-a cells fail to respond to estradiol (E2) treatment or ER antagonism in vitro,
unlike established estrogen-responsive MCF-7 cells (Figure 3.2). Supporting a tumor
cell-independent role of estrogen signaling in malignant progression, ovariectomized
(OVX, estrogen-depleted) wild type mice survived significantly longer than non-OVX,
aged-matched controls after orthotopic tumor challenge in multiple independent
experiments (Figure 3.3A). The effect of OVX is estrogen dependent, as OVX mice
treated with E2 failed to survive as long as OVX mice treated with vehicle (Figure
3.3A). Most importantly however, the survival benefit imparted by ovariectomization
disappeared in tumor-bearing immunodeficient RAG1 KO mice (Figure 3.3B),
indicating that an adaptive immune response is required for the protective effects of
estrogen depletion.
Interestingly, ad libitum estradiol supplementation resulted in augmented
inflammation at tumor (peritoneal) beds (Figure 3.4A). However, the proportions of
antigen experienced (CD44+), recently activated (CD69+) tumor-associated CD4 and
CD8 T cells were significantly higher in OVX tumor-bearing hosts, with corresponding
decreases in estradiol-supplemented animals (Figure 3.4B). Accordingly, the frequency
of T cells isolated from the peritoneal cavity of OVX tumor-bearing mice producing
Interferon (IFN)-γ in response to cognate tumor antigens was significantly higher than
those generated by control mice in conventional ELISpot analysis (Figure 3.4C),
indicative of superior T cell-dependent antitumor immunity. Consistently, tumorassociated T cells from E2-treated mice responded significantly worse than either group
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(Figure 3.4C). Taken together, these results demonstrate that estrogens accelerate
ovarian cancer progression, independent of a direct effect on tumor cells, through a
mechanism that blunts protective antitumor immunity.

Estrogens promote tumor progression in non-ovarian cancer models independent of
any direct effects on neoplastic cell proliferation
The benefits of estrogen depletion were not restricted to ID8-Defb29/Vegf-a
tumors because the progression of male-derived (Sugiura and Stock 1955), estrogeninsensitive (Figure 3.5A), Lewis Lung Carcinomas (LLC-1) tumors was also
significantly delayed in OVX mice, while estradiol supplementation accelerated
malignant growth, ultimately resulting in decreased survival (Figure 3.5B). In addition,
metastatic melanoma B16.F10 cells are not responsive to E2 (Figure 3.6A) in vitro.
However, high doses of E2 given in vivo increased lung metastasis when tumor cells
were injected intravenously (Figure 3.6B & C).

ERα signaling in hematopoietic cells enhances ovarian cancer-induced myelopoietic
expansion
To determine the mechanism by which estrogen signaling accelerates malignant
progression, we next investigated differences in the mobilization of immunosuppressive
cells. We identified strong estrogen-dependent differences only in the accumulation of
myeloid derived suppressor cells (MDSCs), both in the spleen (Figure 3.7A & B) and at
tumor beds (Figure 3.7C & D). Hence, estrogen treatment increased the percentage and
total numbers of both Ly6ChighLy6G- myelomonocytic (M-MDSC) and Ly6C+Ly6G+
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granulocytic MDSCs (G-MDSC) in tumor-bearing mice, while estrogen depletion
through OVX significantly decreased their percentage and total numbers both in the
spleen and at tumor beds (Figure 3.7).
Estrogens primarily signal through the nuclear receptors ERα and ERβ, the former
being expressed in virtually all murine hematopoietic cells (Kovats 2015). Further
supporting that differences in the ovarian cancer immuno-environment are independent of
estrogen signaling on tumor cells, we identified ERα expression in MDSCs derived from
tumor-derived mice (Figure 3.1C). Importantly, myeloid cells sorted from tumorbearing mice were also highly effective at suppressing T cell proliferative responses and
therefore are true immunosuppressive MDSCs and not merely immature hematopoietic
cells (Figure 3.8), supporting their role in estrogen-dependent abrogation of antitumor
immunity. Interestingly, G-MDSCs from E2-depleted (ovariectomized) mice exhibit
weaker immunosuppressive potential compared to vehicle or E2-treated mice.
To confirm that ERα signaling is sufficient to mediate accelerated malignant
progression, we then challenged ERα-/- and wild type control mice with orthotopic ID8Defb29/Vegf-a tumors. As shown in Figure 3.9A, estradiol supplementation failed to
accelerate tumor progression in ERα KO hosts but had significant effects in wild type
controls, indicative that estrogen’s tumor-promoting responses are attributable to ERα
signaling. Additionally, ERα KO mice phenocopy OVX WT mice by surviving
significantly longer than control WT mice. Most importantly, accelerated tumor growth
depends on ERα signaling specifically on hematopoietic cells because in response to E2
treatment, tumors progress significantly faster in lethally irradiated mice reconstituted
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with wild type bone marrow, compared to identically treated mice reconstituted with
ERα-deficient bone marrow (Figure 3.9B).
To determine whether increased MDSC accumulation is sufficient to explain the
increased tumor progression driven by estrogen signaling, MDSCs were depleted from
subcutaneous tumor-challenged OVX mice treated with E2 by daily injection of anti-Gr1
antibody (Figure 3.10). As expected, tumors in OVX mice treated with E2 and IgG
control antibody progressed significantly faster than OVX mice treated with vehicle and
control antibody. However, in OVX mice treated with E2 and anti-Gr1, tumor
progression was delayed and identical to OVX mice treated with vehicle and control
antibody. Together, these results indicate that ERα signaling on hematopoietic cells
accelerates malignant progression independent of stimulation of neoplastic cells, through
a mechanism that results in the mobilization of (ERα+) immunosuppressive MDSCs.

Estrogens signal through ERα on human and mouse myeloid progenitors to boost
the proliferation of regulatory myeloid cells and enhance their immunosuppressive
activity
To rule out that estrogen-dependent myeloid expansion in tumor-bearing mice
was the result of subtle differences in tumor burden or inflammation, we reconstituted
lethally irradiated mice with a 1:1 mixture of CD45.2+ERα-/- and (congenic)
CD45.1+ERα+ bone marrow and challenged them with orthotopic ovarian tumors. As
shown in Figure 3.11A & B, a significantly higher percentage (3.6-fold) of total
(CD11b+Gr-1+) MDSCs arose from ERα+ hematopoietic progenitors, compared to ERαdeficient cells. Because reconstitution of total hematopoietic cells occurred at a similar
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ratio (Figure 3.11A) and MDSCs mobilization took place in the same host under an
identical milieu, dissimilar ERα-dependent MDSC accumulation can only be attributed to
cell-intrinsic ERα+ signaling on myeloid precursors. Notably, we found a preferential
decrease in the expansion of ERα-deficient M-MDSCs, compared to myeloid cells of the
granulocytic lineage (Figure 3.11C).
To understand how estrogen signaling promotes MDSC expansion, we next
differentiated MDSCs in vitro by treating naïve wild type (ERα+) BM with GM-CSF and
IL-6. As reported (Marigo et al. 2010), these inflammatory cytokines induced the
generation of immature myeloid cells that express Ly6G and Ly6C similar to MDSCs
seen in vivo (Figure 3.12A left).
Normal cell culture media drives estrogen signaling due to the presence of various
estrogens in FBS (Briand and Lykkesfeldt 1984) in addition to the estrogenic properties
of phenol red. Blocking the estrogen activity of cell culture media with methylpiperidino
pyrazole (MPP), a selective antagonist of ERα, severely inhibited the expansion of both
M-MDSCs and G-MDSCs, with a preferential effect on the former (Figure 3.12A left &
3.12B), similar to in vivo tumor-bearing mice (Figure 3.11C). In addition, the presence
of ERα antagonists allowed spontaneous differentiation of CD11c+MHC-II+ dendriticlike cells (Figure 3.12A right). Corresponding to in vivo observations (Figure 3.8),
further addition of estradiol resulted in G-MDSCs that were more potently
immunosuppressive while abrogation of ERα signaling prevented the acquisition of
stronger immunosuppressive activity by G-MDSCs (Figure 3.13 top). In contrast,
estradiol did not affect the inhibitory activity of M-MDSCs (Figure 3.13 bottom)
suggesting that the role of estrogens in the accumulation of M-MDSCs is to primarily
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drive their expansion, although the low yields of BM-MDSCs obtained in the presence of
estrogen antagonists precludes testing their suppressive activity.
To support the relevance of ERα signaling in boosting pathological expansion of
MDSCs, we procured bone marrow from 5 different lung cancer patients, and expanded
myeloid cells with GM-CSF and IL-6 (Marigo et al. 2010), in the presence of different
concentrations of an ERα antagonist (MPP). As shown in Figure 3.14, this system
results in reproducible expansion of CD11b+CD33+CD15+CD14-MHC-II- granulocytes
and CD11b+CD33+CD15-/lowCD14+MHC-II- monocytic cells, corresponding to the
human counterparts of granulocytic and monocytic MDSCs. Notably, blockade of ERα
signaling resulted in a dramatic dose-dependent reduction in the expansion of both
MDSC lineages, both at the level of proportions (Figure 3.14A) and absolute numbers
(Figure 3.14B). Together, these data show that estrogen signaling through ERα
influences myelopoiesis in both mice and humans, ultimately boosting the expansion of
MDSCs in response to inflammatory signals; contributing to enhance their
immunosuppressive activity; and blocking their differentiation into MHC-II+ myeloid
cells, overall promoting malignant progression.

Estrogen signaling enhances STAT3 activation through transcriptional upregulation of Janus Kinase 2 (JAK2) and increased total STAT3 expression in
myeloid progenitors
To determine the mechanism by which estrogen signaling promotes MDSC
mobilization, we focused on the effect of estrogen signaling on STAT3 signaling, which
plays a major role in regulating myeloid lineage cells and MDSC expansion (Gabrilovich,
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Ostrand-Rosenberg, and Bronte 2012). As shown in Figure 3.15A, levels of pSTAT3Y705
were significantly increased in monocytic and, to a lesser extent, granulocytic MDSCs
immunopurified from the spleens of advanced ovarian cancer-bearing mice treated with
E2, compared to OVX mice. Accordingly, antiestrogen treatment of in vitro BM-MDSCs
cultures inhibited STAT3 signaling resulting in lower phospho-STAT3 in both MMDSCs and G-MDSCs (Figure 3.15B), indicating that pSTAT3 signaling is enhanced by
estrogen signaling. Finally, E2 supplementation of cell culture media increased phosphoSTAT3 levels with more obvious activity on M-MDSCs (Figure 3.15B).
Interestingly, total STAT3 was up-regulated in tumor-bearing host-derived MMDSCs, likely as a direct effect of estrogen-driven enhanced IL-6 signaling (Suthaus et
al. 2012). Accordingly, antiestrogen drugs down-regulated total STAT3 in BM-derived
M-MDSC (Figure 3.15A & B). However, this difference does not appear to be
transcriptionally regulated, as no differences in STAT3 transcription was observed in MMDSCs and statistically significant but non-correlative differences were observed in GMDSCs (Figure 3.15C). The lack of differences in transcription that correspond to
differences observed in STAT3 protein suggest that turnover of STAT3 protein may
depend on STAT3 activation. To test this hypothesis, progenitor cells isolated from WT
BM were stimulated with 100 ng/mL of IL-6 overnight in the presence of E2 or MPP
(Figure 3.15D). Regardless of treatment, IL-6 triggered strong STAT3 activation. As
expected, in control cells that did not receive IL-6, no STAT3 activation was observed.
More importantly however, in these identical cells, which did not receive IL-6, total
STAT3 levels were also decreased.
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Because STAT3 activation is triggered by IL-6, which was used for in vitro
MDSC expansion, we next investigated the role of estrogen signaling on surface
expression of the IL-6 receptor complex. Treating BM-MDSCs with E2 or antiestrogens
did not elicit changes in surface expression of the IL6Rα chain (Figure 3.16 left) or
Gp130 (Figure 3.16 right), suggesting that estrogen signaling could affect downstream
mediators. We therefore focused on kinase activation, such as Jak2 which mediates
STAT3 phosphorylation, subsequent dimerization, and nuclear translocation following
cytokine receptor engagement (Murray 2007). As shown in Figure 3.17 left, estrogen
supplementation induced transcriptional up-regulation of Jak2 in cytokine-induced bone
marrow MDSCs of both lineages. Most importantly, estradiol also induced a
reproducible Jak2 up-regulation at the protein level (Figure 3.17 right). Therefore, ERα
signaling on myeloid precursors drives MDSC expansion by amplifying IL-6 activity
and, subsequently enhancing JAK-STAT3 signaling. This occurs downstream of the
receptor through up-regulation of total STAT3 and increased Jak2 activity.

Estrogen also impacts other components of the tumor immune-environment
Finally, to rule out that differences in malignant progression due to the direct
effect of estrogens on effector T cells, we performed mixed BM chimera experiments in
which mice received a 1:1 mixture of ERα-/- and congenic wild type BM. Compared to
ERα-/- T cells, E2-responsive wild type CD4 and CD8 T cells display a less activated
phenotype characterized by lower expression of CD44 (Figure 3.18A). Correspondingly,
the frequencies of wild type T cells responding to tumor antigens in IFN-γ ELISpot re-
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challenge assays were lower than those of their counterpart ERα-/- T cells, sorted from the
same microenvironment (Figure 3.18B).
To determine the relative importance of these differences in direct ERα signaling
in T cells, independently of estrogen-dependent MDSC activity, wild type and ERα-/- T
cell splenocytes were identically enriched for tumor-reactive populations by ex vivo
priming against tumor lysate-pulsed BMDCs (Y. Nesbeth et al. 2009; Y. C. Nesbeth et al.
2010), and then adoptively transferred into ovarian cancer-bearing mice at days 7, 14, and
21. Confirming previous reports (Y. Nesbeth et al. 2009; Y. C. Nesbeth et al. 2010), both
wild type and ERα-/- T cells significantly extended survival; however, there was no
difference between wild type and ERα KO T cells regardless of whether mice were
treated with E2 (Figure 3.19A). Therefore, while E2 does have a measurable T cellintrinsic effect, this is not sufficient to drive differences in malignant progression, and,
therefore, its effect on immunosuppressive cells, namely MDSCs, is the main driver
underlying estrogen-driven tumor acceleration.
To further support our hypothesis that estrogen depletion creates a less
suppressive immune microenvironment as well as to determine its effect on cell-based
immunotherapies, we challenged WT control or OVX mice with ID8-Defb29/Vegf-a
tumors and treated them with a single, suboptimal adoptive transfer of antigen-primed T
cells or antigen-pulsed DCs at day 7 (Figure 3.19B). Because only one dose of T cells
was given, T cell administration failed to significantly increase survival as seen in Figure
3.19A, and there was no combinatory effect with OVX. DC vaccination did however
elicit a survival increase. This effect synergized with OVX resulting in significant
survival advantage in mice receiving both OVX and DC vaccination compared to mice
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that only received only one of the treatments (OVX or DCs). These data further
emphasize the potentiating effect of E2 on the immunosuppressive tumor
microenvironment and suggest that combining antiestrogen therapies with
immunotherapies may be clinically beneficial.
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Discussion
Here we show that ERα signaling on myeloid precursors is a major contributor to
pathological myelopoiesis in cancer, resulting in MDSC expansion and augmented
immunosuppressive activity. Accordingly, ovariectomized mice exhibit delayed
malignant progression upon challenge with different estrogen insensitive tumor models,
while E2 supplementation has the opposite effects. Supporting the crucial role of
spontaneous antitumor immunity in this mechanism, differences in tumor growth
disappear in T cell-deficient mice.
Although the role of estrogen signaling in the progression of breast tumors and a
subset of ovarian cancer patients has been underscored by the clinical use of ER
antagonists, our results demonstrate that estrogens have a profound effect on antitumor
immunity and tumor-promoting inflammation, independent of their direct activity on
tumor cells. Our data therefore provide novel mechanistic insight into how enhanced
estrogenic activity contributes to malignant progression in established tumors.
Furthermore, our data support that novel antiestrogen drugs that, unlike tamoxifen (Gallo
and Kaufman 1997), have no agonistic effects on non-breast cell types, may have
benefits in a wide range of cancers in pre-menopausal women, independently of the
expression of ERs in tumor cells. Therefore, antiestrogens, especially when used as an
adjuvant therapy, may synergize with immunotherapies such as checkpoint inhibitors to
significantly extend survival. Thus, while bilateral oophorectomy is standard in ovarian
cancer treatment, our data suggest that ER- breast tumors and other malignancies in at
least female cancer patients in their reproductive age could be delayed by specifically
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blocking ERα in a systemic manner, especially if complementary immunotherapies are
implemented as adjuvant therapy.
Our results also have implications to understand gender-dependent differences in
tumor initiation and malignant progression in different malignancies. This may be
particularly relevant in BRCA1-mutation carriers, where augmented estrogenic signal has
been recently demonstrated (Widschwendter et al. 2013). Furthermore, ERα expression
is regulated by BRCA1-dependent ubiquitination (Eakin et al. 2007), so that cancerpredisposing heterozygous BRCA1 mutations could result in increased ER expression,
and therefore increase estrogen activity. Whether mobilization of MDSCs in the context
of additional inflammatory signals contributes to tumor initiation in BRCA1 mutation
carriers demands further experimental proof, but our study suggests this as a likely
pathogenic mechanism.
This study finally contributes to the understanding of the complexity of factors
deregulating myelopoiesis (and therefore antigen presentation) in virtually all solid
tumor-bearing hosts. Our data indicate that ERα signaling has a triple effect on myeloid
bone marrow progenitors by altering pSTAT3 signaling, which drives both expansion and
increased survival in these cells (Gabrilovich, Ostrand-Rosenberg, and Bronte 2012): on
the one hand, estrogens up-regulate JAK2, which mediates STAT3 phosphorylation, as
well as total STAT3 itself. Therefore, estrogenic activity prepares the bone marrow for
acute expansion of myeloid precursors, but estrogen-dependent mobilization of MDSCs
only occurs in the presence of direct inflammatory signals that activate JAK kinases
(typically, IL-6), and not necessarily in a cyclic manner during the menstrual cycle.
Accordingly, incubation with E2 alone does not result in myeloid expansion in vitro,
51

while combinations of IL-6, GM-CSF and E2 drive MDSC mobilization to a much
greater extent than cytokines alone (Figure 1.2). These mechanisms appear to be
important during pregnancy, where estradiol also drives the expansion and activation of
MDSCs (Pan et al. 2016), but our study demonstrates their relevance in the pathogenesis
of women’s malignancies.
In summary, our study unveils the role of estrogen signaling in pathological
myelopoiesis, and supports that more specific antiestrogen drugs could complement
emerging immunotherapies to significantly extend the survival of cancer patients,
independently of the expression of ERs in tumor cells.
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Figures
Figure 3.1

Figure 3.1: Estrogen receptor α is expressed by non-neoplastic cells in the ovarian tumor
microenvironment
A, Immunohistochemistry of human ovarian tumor sections were stained for ERα (scale
bar indicates 10 µm). Positive tumors (left) express ERα in neoplastic as well as normal
cells found in the tumor microenvironment. In negative tumors (right), ERα expression
can only be found in tumor-infiltrating cells. B, Hematopoietic myeloid (CD45+CD11b+)
and non-myeloid (CD45+CD11b-) cells were FACS-isolated from human ovarian tumors
or bone marrow (BM) and ERα expression was confirmed by reverse transcription PCR.
MCF-7 and MDA-MB-231 cDNA served as a positive and negative controls,
respectively. Water was used for a no template control (NTC). C, Via western blot,
mouse ovarian ID8-Defb29/Vegf-a tumor cells do not express ERα, while MDSCs
(CD11b+Gr-1+) isolated from in vivo ID8-Defb29/Vegf-a tumors do.
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Figure 3.2

Figure 3.2: ID8-Defb29/Vegf-a proliferation is unaffected by direct estrogen signaling
ID8-Defb29/Vegf-a cells grown in vitro in estrogen-depleted steroid-free media (SFR10)
do not respond to E2 supplementation, unlike the known E2-responsive control MCF-7
cells (left). Similarly, antiestrogen (fulvestrant) treatment of cells grown in estrogen
containing normal media had no effect (right). Proliferation was determined by MTS
assay. Proliferation is expressed in arbitrary units (A.U.) calculated by normalizing the
absorbance of each condition to the average absorbance of the cell type’s vehicle control.
Significant differences between vehicle and treated samples were determined by
confirming Gaussian distribution and subsequent T-testing. Asterisks (*) indicate
significant difference (p < 0.05) from vehicle-treated cells.
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Figure 3.3

Figure 3.3: Estrogen depletion increases ID8-Defb29/Vegf-a survival, but only in
immunocompetent mice
A, Estrogen-depleted, ovariectomized (OVX) wild type mice survive significantly longer
than control sham-operated mice challenged with i.p. ID8-Defb29/Vegf-a tumors. B,
OVX fails to increase survival in immunodeficient RAG1 KO mice. Experiments were
repeated three times with n=5 mice per group each time. Significance was calculated via
Log-rank testing with p < 0.05 deemed significant, and asterisk (*) indicates significant
difference between WT+Vh and other treatment groups. Representative data is shown.
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Figure 3.4

Figure 3.4: E2 decreases the ability of endogenous T cells to respond to tumor antigens
A, Tumor bearing mice treated with E2 have significantly increased T cell accumulation
compared to vehicle or OVX treated mice. N=5 mice per group. B, The proportions of
activated (CD44+CD69+) tumor-associated CD4 and CD8 T cells is higher in OVX
compared to E2-treated mice. C, A larger proportion of T cells isolated from OVX mice
are able to respond to cognate tumor antigens in ELISpot re-challenge assays compared
to Vh or E2 treated mice. Gaussian distributions were determined by KolmogorovSmirnoff tests. Significance between treatment groups was determined by T-tests or
Mann-Whitney tests. Asterisk (*) indicates p < 0.05.
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Figure 3.5

Figure 3.5: Estrogens affect LLC-1 tumor progression independent of direct cancer-cell
intrinsic signaling
A, LLC-1 cells grown in E2-depleted SFR10 media do not increase proliferation in
response to E2, unlike E2-responsive MCF-7 cells (left). Proliferation of LLC-1 cells
grown in normal E2-containing media are not inhibited by the antiestrogen fulvestrant,
unlike MCF-7 cells (right). Proliferation was determined by MTS assay and calculated as
arbitrary units (A.U.) by normalizing absorbance to the average absorbance of vehicletreated cells. B, OVX significantly impairs progression in intraperitoneal (IP) and
subcutaneous (SQ) tumors, while E2 treatment significantly increases progression in SQ
LLC-1. Asterisks (*) indicate significant difference (p < 0.05) from vehicle conditions,
calculated by T-testing.
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Figure 3.6

Figure 3.6: Estrogens affect B16.F10 metastasis via cancer-cell extrinsic mechanisms
A, B16.F10 cells fail to respond to E2 or antiestrogen (MPP) treatment in vitro. B, E2
treatment increases the number of tumor foci found in lungs of mice (n=5 per group)
injected intravenously with B16.F10 cells after 2 weeks, as determined by hematoxyline
and eosin staining. C, Quantification of number of tumor foci in lungs. Asterisk (*)
indicates significant difference from vehicle calculated by T-test, p < 0.05.
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Figure 3.7

Figure 3.7: E2 increases MDSC accumulation in tumor-bearing mice
A & B, E2 increases the proportion and total numbers of M- and G-MDSCs in the
spleens of ID8-Defb29/Vegf-a intraperitoneal tumor bearing female mice (n=5 mice per
group). C & D, Similar increases in MDSCs are seen in the peritoneal wash of these
mice. Significance was determined by T-tests. Double asterisks (*/*) indicate significant
difference (p < 0.05) in both M- and G-MDSCs between treatment groups. Single
asterisk (*) indicates significant difference (p < 0.05) in G-MDSCs between groups.
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Figure 3.8

Figure 3.8: MDSCs from tumor-bearing mice are immunosuppressive
MDSCs isolated from the peritoneal wash of i.p. ID8-Defb29/Vegf-a tumor bearing mice
were co-cultured with naïve T cells activated with anti-CD3/28 beads, and proliferation
was determined via dilution of CellTrace Violet after 3 days. M-MDSCs from Vh, E2,
and OVX mice are all potently suppressive, but G-MDSCs from OVX mice are far less
suppressive than those from Vh and E2 treated mice.
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Figure 3.9

Figure 3.9: Hematopoietic ERα activity is required for maximal response to E2
A, WT and ERα KO mice were treated with vehicle or estrogen and challenged with i.p.
ID8-Defb29/Vegf-a tumors. Results shown are pooled from three independent
experiment using n=5 mice per group. B, Following lethal irradiation, mice were
reconstituted with WT or KO BM, treated with Vh or E2, and challenged with i.p. tumors
(n=5 mice per group). Significance between groups was determined by Log-rank test.
Asterisk (*) indicates p < 0.05.
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Figure 3.10

Days
Figure 3.10: MDSCs are required for E2 to increase tumor progression
Ovariectomized WT C57BL/6 mice were subcutaneously injected with 1X104 A7C11
(syngeneic p53 null, oncogenic Kras-driven) breast cancer cells in matrigel and treated
with vehicle (0.1% EtOH) or E2 (10 µM) drinking water. Starting two days after tumor
challenge, mice received daily injections of 250 µg of isotype control IgG or anti-Gr1
antibody (RB6-8C5). Tumors were measured twice per week for 15 days. Statistically
significant differences between mean tumor volumes was determined by T-test once
normal distribution was confirmed via Kolmogorov-Smirnov testing. Significant
differences were defined using a p < 0.05, and asterisks (**) indicates significant
differences between the OVX+E2+irrelevant IgG group (n=5) and each of the
OVX+E2+anti-Gr1 (n=5) and OVX+Vh+iIgG groups (n=5), tested separately.
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Figure 3.11

Figure 3.11: Cell-intrinsic ERα signaling increases the proportion of WT relative to ERα
KO MDSCs in mixed BM chimeras
A & B, Mice reconstituted with a 1:1 mix of WT CD45.1 and KO CD45.2 BM equally
repopulate lethally irradiated hosts. Within the same hosts challenged with ID8Defb29/Vegf-a intraperitoneal tumors, WT BM was significantly more effective at
producing CD11b+Gr-1+ splenic MDSCs than KO BM. C, In an independent mixed BM
chimera experiment, WT BM results in proportionally (as a percent of CD11b+MHC-IIcells) more M-MDSC in the spleen compared to KO BM. Significance was determined
by Mann-Whitney testing. Asterisk (*) indicates p < 0.05.
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Figure 3.12

Figure 3.12: In vitro mouse BM-MDSDC differentiation is skewed towards a DC-like
phenotype upon ERα inhibition
A, The differentiation of WT mouse BM cultured in 40 ng/mL GM-CSF + 40 ng/mL IL6 into M- and G-MDSCs is impaired in the presence of the ERα antagonist MPP (left).
Instead of becoming MDSCs, MPP skews myeloid differentiation in favor of
CD11c+MHC-II+ DC-like cells (right). B, Total cell yields of M- and G-MDSCs are
decreased when treated with MPP. Significance was determined by T-tests. Asterisk (*)
indicates p < 0.05.
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Figure 3.13

Figure 3.13: While all BM-MDSCs are immunosuppressive, E2 is required for maximal
G-MDSC suppression
BM-derived MDSCs were co-cultured with CellTrace Violet labeled T cells activated
with anti-CD3/CD28 beads at different ratios. T cell proliferation was determined by
CellTrace Violet dilution after 3 days. G-MDSCs from E2-augmented cultures were able
to effectively suppress T cell proliferation down to a 1:16 ratio of MDSCs to T cells
while Vh BM-MDSCs required a 1:4 ratio. MPP G-MDSCs had only marginal effects on
T cell proliferation even at a 1:4 ratio (top). M-MDSCs from Vh and E2 treated cultures
were equally suppressive (bottom).
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Figure 3.14

Figure 3.14: Human BM-MDSC expansion is impaired by antiestrogen treatment
A & B, Human BM from lung cancer patients was cultured in normal media containing
40 ng/mL GM-CSF + 40ng/mL IL-6 resulting in M-MDSCs (CD11b+CD33+CD14+) and
G-MDSCs (CD11b+CD33+CD15+). Treating with increasing doses of MPP significantly
impaired the total number of M- and G-MDSCs produced in these cultures without
decreasing the overall proportion of viable cells indicating that the effects of MPP are not
merely cytotoxic. Significance was determined by T-tests comparing each treatment
groups to the vehicle control group. Asterisk (*) indicates p < 0.05.
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Figure 3.15

Figure 3.15: Estrogen signaling is required for optimal STAT3 activation in MDSCs
A, MDSCs were isolated from the peritoneal cavity and spleen of ID8-Defb29/Vegf-a
intraperitoneal tumor bearing mice treated by OVX or E2 and analyzed via western blot.
E2 increased STAT3 activation in in vivo MDSCs. B, In vitro cytokine derived BMMDSCs also require ERα signaling for optimal STAT3 activation. Additionally, in MMDSCs, total STAT3 is decreased by estrogen inhibition. C, Quantitative real time PCR
of M- and G-BM-MDSCs fail to show changes in STAT3 transcription that correspond
with protein levels. Therefore, regulation of STAT3 likely occurs post-translationally.
D, BM progenitor cells stimulated overnight with a high dose of 100 ng/mL IL-6 are able
to activate STAT3 regardless of E2 or MPP treatment. Without IL-6, these cells do not
activate STAT3, and total STAT3 levels are diminished. Significance compared to
vehicle was determined by Mann-Whitney testing. Asterisk (*) indicates p < 0.05.
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Figure 3.16

Figure 3.16: IL-6 receptor is not decreased by antiestrogen treatment
BM-MDSCs were stained for surface expression of the IL6Rα chain (CD126) and Gp130
(CD130). Instead of decreasing the MFIs of IL6Rα and Gp130 in MPP treated cells,
slight increases were observed. E2 had no effect on IL6Rα and Gp130 compared to
vehicle.
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Figure 3.17

Figure 3.17: Jak2 expression is increased by E2 treatment
Compared to vehicle, BM-MDSCs treated with E2 significantly up-regulate Jak2 at both
the RNA (left) and protein level (right). Significant differences compared to vehicle was
determined by Mann-Whitney testing. Asterisk (*) indicates p < 0.05.
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Figure 3.18

Figure 3.18: ERα has cell-intrinsic inhibitory effects on tumor infiltrating T cells
A, Mice were reconstituted with a 1:1 mix of WT CD45.1 and ERα KO CD45.2 BM and
challenged with intraperitoneal ID8-Defb29/Vegf-a tumors. WT T cells within the same
tumor microenvironment had a less activated phenotype compared to their counterpart
KO T cells. B, WT and KO T cells sorted from the tumor microenvironment were
subsequently re-stimulated with tumor antigen-pulsed BMDCs in ELISpot assay. A
significantly higher proportion of KO T cells responded to cognate antigens compared to
WT T cells by producing IFN-γ. Significance was determined by T-testing. Asterisk (*)
indicates p < 0.05.
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Figure 3.19

Figure 3.19: The overall effect of E2 on the immune microenvironment is more
important than its direct effect on T cell inhibition
A, Tumor challenged WT mice treated with vehicle or E2 received multiple doses of
antigen-primed WT or ERα KO T cells resulting increased survival (n=5 mice per group).
However, irrespective of E2 treatment, WT and KO T cells were equally effective. B,
Tumor challenged WT vehicle or OVX treated mice were given cell-based
immunotherapies in the form of antigen-primed T cells or DC vaccination. No
significant survival advantage was observed in OVX mice receiving T cells compared to
OVX control mice; however, OVX mice receiving DC vaccination did survive
significantly longer compared to OVX control mice. Significance was determined by
Log-rank testing with p< 0.05 deemed significant. Asterisks (*) indicate increased
survival compared to non-OVX control mice and hash (#) indicates increased survival
compared to OVX control mice.
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CONCLUSIONS AND FUTURE DIRECTIONS
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Conclusions
This work demonstrates that estrogens have an important role in shaping the
tumor microenvironment. In the absence of estrogen signaling, antitumor T cells are able
to significantly delay tumor progression. While estrogen signaling has direct effects on T
cells, including impairing Th1 CD4 differentiation, these effects do not account for all of
estrogen’s effects on tumor progression, as E2 treatment is capable of accelerating tumor
progression in T cell-lacking RAG1 KO mice. This work shows for the first time, that
estrogen signaling increases the accumulation of MDSCs, which accelerate tumor
progression through a variety of mechanisms that include suppressing T cell responses.
The mechanism of E2 on MDSCs appears to be increased the JAK2-STAT3 signaling via
increased JAK2 expression. This work also demonstrates that estrogen depletion is
capable of augmenting the benefit of DC vaccine-based immunotherapy. Therefore,
antiestrogen therapies have clinical potential, especially in combination with emerging
immunotherapies.
Estrogens are capable of directly influencing multiple “hallmarks of cancer”
(Figure 1.1), such as cell proliferative and anti-apoptotic mechanisms. As a result,
antiestrogen therapies, such as tamoxifen, have been used extremely effectively as
adjuvant therapy for ER+ breast cancer. I believe that this success has actually limited
consideration of estrogen in other estrogen-independent tumors by focusing the field
solely on how these early antiestrogen drugs affects neoplastic cells. In a few small
clinical trials conducted in the relatively nascent stages of estrogen therapy, tamoxifen
was used as salvage therapy in non-ER+ breast cancers, such as ovarian cancer.
However, partly due to the fact that these are such late stage treatment-resistant tumors,
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little clinical benefit was observed. This may be addressed by using antiestrogens earlier
in cancer treatment, especially immediately following surgical resection, at which point
there is clinically no “evidence of disease.”
Our findings in preclinical models that estrogen depletion can increase antitumor
immunity suggest that there may only be a limited window, such as in early tumor
immune responses, where antiestrogen therapy can be effective. However, with the
advent of immunotherapies, especially cell-based immunotherapies, it may be possible to
re-open or extend this window. It is also important to note that clinical trials have
demonstrated that antiestrogen therapies are generally well-tolerated, which makes them
attractive candidates to be combined with other therapies.
Another problem in early clinical trials with antiestrogens has been the reliance on
tamoxifen. Tamoxifen is a selective estrogen receptor modulator (SERM) meaning that
depending on specific cell type, tamoxifen can either act as an agonist or antagonist.
Therefore, tamoxifen may actually serve as an agonist in non-neoplastic cell responses to
tumors. Pure antagonists may therefore be an attractive option in future studies and
treatments centered on inhibiting estrogen signaling.
Further complicating matters, it is now recognized that there are multiple
receptors for estrogen, which are dynamically expressed and mediate different, at times
contradictory, responses. Therefore, non-specific targeting of estrogen signaling using
pan-inhibitors, like fulvestrant, or targeting estrogen production, by inhibiting aromatase
using drugs like letrozole, may have variable effects. Newer, subtype specific
antagonists may therefore provide more consistent effects.
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Our work supports findings by others that the effect of estrogen signaling on
specific cells is context dependent. It is now clear that the direct proliferative responses
of breast and endometrial epithelial cells triggered by estrogen stimulation alone is rare.
Instead, the estrogen signaling network interacts with other signaling networks, such as
cytokine-induced activation, resulting in attenuated or increased cytokine responses, or
even completely novel effects. In our work, it is important to acknowledge that most of
the data were generated using one model of ovarian cancer, ID8-Defb29/Vegf-a, which,
like all tumors, acquires a unique microenvironment. While this model does recapitulate
key features of ovarian cancer, it is still just one model. Therefore, other tumor models
may elicit different milieu of inflammatory cytokines, which may alter the effect of E2 on
tumor progression. Nevertheless, our data, showing the ability of E2 to accelerate LLC-1
and B16.F10 models independent neoplastic cell proliferation, in combination with
literature, supporting the role of estrogen in increasing myeloid and humoral immune
responses, support our overall hypothesis that estrogen is capable of promoting malignant
progression in a variety of tumor settings.
This work is also particularly enlightening when considering how pervasive yet
unacknowledged estrogens are in research and in health. Typical cell culture media is
highly estrogenic due to the presence of FBS and phenol red. This may underlie
anecdotal reports that cell behavior tends to vary depending on company and batch of
media used. Most mouse studies use ovary-intact females of reproductive age fed a
standard diet containing phytoestrogens. Additionally, estrogen levels fluctuate
according to menstrual cycle. Our data suggest that these are important factors capable
of influencing tumor progression. Indeed, it is already well known that certain preclinical
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tumor models progress differently in male versus female mice. Estrogens are likely a key
reason for this sexual dimorphism.

Future Directions
This work demonstrates that STAT3 activation in myeloid cell differentiation is
affected by ERα signaling; however, a number of questions revolving around this
mechanism still remain unanswered. ERα, as a transcription factor, binds DNA estrogen
response elements (EREs) or may be tethered to non-ERE DNA. It remains to be
determined which specific genes are being directly regulated by ERα. This can be
addressed by Chromatin Immunoprecipitation Sequencing (ChIP-seq). Challenges to this
approach lie in finding a ChIP-grade antibody capable of specifically pulling down
mouse ERα, in addition to acquiring enough cells.
Another important piece of data from our study that raises unanswered questions
was the finding that the immunosuppressive potential of G-MDSCs positively correlates
with estrogen treatment. G-MDSC from MPP treated cultures were weakly suppressive
while G-MDSCs from E2 augmented cultures were more highly suppressive. It is
unclear how E2 is affecting G-MDSC suppression. For example, E2 may increase
arginase production, the release of reactive oxygen or nitrogen species, or other
immunosuppressive cytokines. More complete transcriptome profiling would provide
major insight into how E2 perturbs G-MDSC function.
In addition to ERα, additional estrogen receptors, ERβ and GPER, are expressed
by leukocytes. A major limitation of this work was the sole focus on ERα. Especially in
vivo it is likely that ERβ and GPER are partially responsible for the overall tumor76

promoting response of E2. Knockout mice and pharmacological inhibitors exist that
would allow further study in this direction. In particular, generating mixed BM chimeras
using ERβ KO mice would allow study of hematopoietic tumor microenvironment cellintrinsic effects directly attributable to ERβ status.
Additionally, all of these estrogen receptors have been reported to be expressed
by other immune cells not directly examined in this study, such as NK and B cells. It is
also likely that estrogens affect their function further contributing to the tumor-promoting
effect of E2 treatment in vivo.
While there remain many unanswered questions, we have found a novel
mechanism for E2-accelerated tumor progression independent of neoplastic cell
signaling. This finding has important implications in clinical practice as well as basic
science research due to the nearly ubiquitous, but largely ignored presence of estrogenic
molecules in health and research. By demonstrating potent tumor promotion via altered
responses to tumor-derived inflammation, our work emphasizes that estrogen is a
multifaceted and crucial factor to consider in a wide variety of clinical settings and
laboratory studies.
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